| __timestamp | Corcept Therapeutics Incorporated | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 11606000000 |
| Thursday, January 1, 2015 | 36949000 | 10313000000 |
| Friday, January 1, 2016 | 45240000 | 9762000000 |
| Sunday, January 1, 2017 | 62416000 | 9830000000 |
| Monday, January 1, 2018 | 81289000 | 10102000000 |
| Tuesday, January 1, 2019 | 100359000 | 10615000000 |
| Wednesday, January 1, 2020 | 105326000 | 8955000000 |
| Friday, January 1, 2021 | 122356000 | 9634000000 |
| Saturday, January 1, 2022 | 152848000 | 10042000000 |
| Sunday, January 1, 2023 | 184259000 | 10504000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. Over the past decade, from 2014 to 2023, Merck & Co., Inc. and Corcept Therapeutics Incorporated have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses.
Merck, a global leader, consistently allocated a significant portion of its budget to SG&A, with expenses peaking at approximately $11 billion in 2014. Despite fluctuations, Merck's SG&A costs remained relatively stable, reflecting its robust market position and strategic investments.
Conversely, Corcept Therapeutics, a smaller player, exhibited a remarkable growth trajectory in SG&A expenses, surging by over 400% from 2014 to 2023. This increase underscores Corcept's aggressive expansion strategy and commitment to scaling its operations.
These insights reveal the diverse strategies employed by pharmaceutical companies to navigate the complexities of the industry.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Incyte Corporation and Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated and Perrigo Company plc: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs MorphoSys AG Trends and Insights
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.